Yutong Zhang
Research Subjects
Yutong Zhang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Hong Xu
School of Biomedical Engineering Shanghai Jiao Tong University Shanghai China
2 shared publications Feiyang Ou
School of Biomedical Engineering
1 shared publication- Feng Shen
School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
1 shared publication Heni Wang
School of Biomedical Engineering
1 shared publicationHongchen Gu
School of Biomedical Engineering
1 shared publication- Hongchen Gu
School of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, China
1 shared publication
Latest Publications
- 15 December 2025
- Published by American Chemical Society (ACS) in ACS Sensors
Barcode-Based SlipChip for High-Multiplexed and Trace Sample Digital Quantification with Femtomolar Sensitivity
The development of the digital enzyme-linked immunosorbent assay (ELISA) has improved the detection of low-abundance protein biomarkers in biological samples, achieving a 1000-fold increase in sensitivity compared to conventional protein detection methods. However, existing digital ELISA technologies encounter difficulties in simultaneously identifying numerous protein biomarkers at ultralow concentrations, particularly in trace samples. This limitation calls for improvements in both detection multiplicity and sensitivity. Herein, a simple digital ELISA platform, the Barcodes Integrated SlipChip (BIS-chip), was developed for the ultrasensitive identification of multiple proteins from trace samples. The BIS-chip employs a two-step loading method that eliminates substrate precatalysis, thereby ensuring the specificity of 10-plex target detection. Additionally, its high bead-loading efficiency improves the assay sensitivity for each target. By counting digital "On" and "Off" signals, the BIS-chip quantifies a panel of 10 cytokines with low limits of detection (LoD) in the femtogram per milliliter (fg/mL) range, achieving a sensitivity improvement of several orders of magnitude compared with standard highly multiplexed suspension array technology. To validate its clinical applicability, the BIS-chip was used to simultaneously measure 10 cytokines from only 20 μL of intralesional plasma of patients diagnosed with oral lichenoid reactions (OLRs), a condition where cytokines are typically undetectable via commercial multiplexed immunoassays. Supported by machine-learning algorithms, the OLR diagnostic models were successfully developed with 95.7% sensitivity and 100% specificity. With its exceptional detection multiplicity, ultrasensitivity, and straightforward workflow, the BIS-chip provides an innovative solution for the quantitative analysis of clinical low-abundance biomarkers in trace samples.
- 15 December 2025
- Published by American Chemical Society (ACS) in ACS Sensors
Barcode-Based SlipChip for High-Multiplexed and Trace Sample Digital Quantification with Femtomolar Sensitivity
The development of the digital enzyme-linked immunosorbent assay (ELISA) has improved the detection of low-abundance protein biomarkers in biological samples, achieving a 1000-fold increase in sensitivity compared to conventional protein detection methods. However, existing digital ELISA technologies encounter difficulties in simultaneously identifying numerous protein biomarkers at ultralow concentrations, particularly in trace samples. This limitation calls for improvements in both detection multiplicity and sensitivity. Herein, a simple digital ELISA platform, the Barcodes Integrated SlipChip (BIS-chip), was developed for the ultrasensitive identification of multiple proteins from trace samples. The BIS-chip employs a two-step loading method that eliminates substrate precatalysis, thereby ensuring the specificity of 10-plex target detection. Additionally, its high bead-loading efficiency improves the assay sensitivity for each target. By counting digital "On" and "Off" signals, the BIS-chip quantifies a panel of 10 cytokines with low limits of detection (LoD) in the femtogram per milliliter (fg/mL) range, achieving a sensitivity improvement of several orders of magnitude compared with standard highly multiplexed suspension array technology. To validate its clinical applicability, the BIS-chip was used to simultaneously measure 10 cytokines from only 20 μL of intralesional plasma of patients diagnosed with oral lichenoid reactions (OLRs), a condition where cytokines are typically undetectable via commercial multiplexed immunoassays. Supported by machine-learning algorithms, the OLR diagnostic models were successfully developed with 95.7% sensitivity and 100% specificity. With its exceptional detection multiplicity, ultrasensitivity, and straightforward workflow, the BIS-chip provides an innovative solution for the quantitative analysis of clinical low-abundance biomarkers in trace samples.
- Open Access
- 21 November 2023
- Published by Royal Society of Chemistry (RSC) in Sensors & Diagnostics
- Vol. 3 (1) , 9-27
Recent progress in digital immunoassay: how to achieve ultrasensitive, multiplex and clinical accessible detection?
The detection of low-abundance proteins in physiological samples is of high importance in clinical diagnostics and pathology research. However, protein biomarkers that can be accurately quantified by the existing detection methods and applied to clinical practice are just the tip of the iceberg. Quite a few proteins with concentrations below pg mL−1, which are closely related to the occurrence and progression of diseases, are not effectively utilized due to the limitations of detection technology. In addition, simultaneously measuring multiple proteins in a single reaction improves the diagnostic accuracy and reliability since most diseases will cause abnormal changes in multiple biomarkers. Therefore, increasing demands to realize ultrasensitive and multiplexed protein detection have promoted the rapid development of digital immunoassay recently. Furthermore, the high-end digital detection is also expected to spark its potential for streamlined and integrated workflows in clinical applications, extending beyond its use in fundamental research within central laboratories. In this review, we focus on elucidating the core strategies and approaches to enhance the performance of digital immunoassay across three key dimensions: sensitivity, multiplexing, and clinical accessibility. Ultimately, we highlight the promising prospects of digital protein detection in the next decade.
- 21 November 2023
- Published by Royal Society of Chemistry (RSC) in Sensors & Diagnostics
- Vol. 3 (1) , 9-27
Open AccessRecent progress in digital immunoassay: how to achieve ultrasensitive, multiplex and clinical accessible detection?
The detection of low-abundance proteins in physiological samples is of high importance in clinical diagnostics and pathology research. However, protein biomarkers that can be accurately quantified by the existing detection methods and applied to clinical practice are just the tip of the iceberg. Quite a few proteins with concentrations below pg mL−1, which are closely related to the occurrence and progression of diseases, are not effectively utilized due to the limitations of detection technology. In addition, simultaneously measuring multiple proteins in a single reaction improves the diagnostic accuracy and reliability since most diseases will cause abnormal changes in multiple biomarkers. Therefore, increasing demands to realize ultrasensitive and multiplexed protein detection have promoted the rapid development of digital immunoassay recently. Furthermore, the high-end digital detection is also expected to spark its potential for streamlined and integrated workflows in clinical applications, extending beyond its use in fundamental research within central laboratories. In this review, we focus on elucidating the core strategies and approaches to enhance the performance of digital immunoassay across three key dimensions: sensitivity, multiplexing, and clinical accessibility. Ultimately, we highlight the promising prospects of digital protein detection in the next decade.